Loading
These consensus rules judge response in mycosis fungoides and Sezary syndrome across skin, lymph nodes, blood and organs, because these lymphomas behave unlike other lymphomas.
Trials in mycosis fungoides and Sezary syndrome, the main cutaneous T-cell lymphomas, lacked standard evaluation, staging, endpoints and response criteria. A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium and the EORTC Cutaneous Lymphoma Task Force (Olsen and colleagues, Journal of Clinical Oncology 2011) set out how trials should be run, how to assess disease in skin, lymph nodes, blood and organs, and how endpoints and response are defined.
Shares Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Complete response (CR) and partial response (PR), Lugano classification / Ann Arbor staging.
Shares Mycosis fungoides, Sezary syndrome, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).
Shares Mycosis fungoides, Sezary syndrome.
Shares Complete response (CR) and partial response (PR), Lugano classification / Ann Arbor staging.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/